Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis

Reuters

07-18

<a href="https://laohu8.com/S/VTRS">Viatris Inc.</a> Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis

Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE32851) on July 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2552464452"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552464452\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2552464452?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552464452","market":"fut","top_or_hot":-1,"title":"Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VTRS\">Viatris Inc.</a> Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE32851) on July 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-18 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VTRS\">Viatris Inc.</a> Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE32851) on July 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL1XjCnT:1","article_id":"2552464452","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552464452","pubTimestamp":1752836361,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis. Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide acc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4588":"碎股","VTRS":"Viatris Inc.","BK4007":"制药","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4583":"猴痘概念"},"translate_title":"Viatris Inc.宣布MR-142和MR-141 3期试验的积极结果，并提供MR-139睑缘炎研究的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9},"content_text":"Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis\n    \n\n        Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE32851) on July 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}